Phase 3 Pancreatic Adenocarcinoma Clinical Trials

15 recruitingPhase 3

What is a Phase 3 trial?

Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.

Showing 115 of 15 trials

Recruiting
Phase 3

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more
Revolution Medicines, Inc.500 enrolled17 locationsNCT07252232
Recruiting
Phase 3

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Immuneering Corporation510 enrolled3 locationsNCT07562152
Recruiting
Phase 3

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

Pancreatic CancerMetastatic Pancreatic CancerMetastatic Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc.614 enrolled13 locationsNCT07409272
Recruiting
Phase 3

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Pancreatic CancerPancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic+5 more
Revolution Medicines, Inc.900 enrolled2 locationsNCT07491445
Recruiting
Phase 3

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Adenocarcinoma+2 more
SWOG Cancer Research Network94 enrolled274 locationsNCT06998940
Recruiting
Phase 2Phase 3

Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX

Resected Pancreatic Adenocarcinoma
University Hospital, Rouen390 enrolled1 locationNCT07044453
Recruiting
Phase 3

The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer

Metastatic Pancreatic CancerVenous ThromboembolismLocally Advanced Pancreatic Adenocarcinoma
Quercis Pharma AG480 enrolled3 locationsNCT06861088
Recruiting
Phase 2Phase 3

Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency

Pancreatic AdenocarcinomaHomologous Recombination Deficiency
Fudan University30 enrolled1 locationNCT06095141
Recruiting
Phase 3

Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma
Fudan University210 enrolled1 locationNCT06250972
Recruiting
Phase 3

Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.

Pancreatic Adenocarcinoma Advanced or Metastatic
Gruppo Oncologico del Nord-Ovest340 enrolled28 locationsNCT06897644
Recruiting
Phase 3

Evaluating Novel Therapies in ctDNA Positive GI Cancers

Hepatocellular CarcinomaGastric AdenocarcinomaPancreatic Adenocarcinoma+4 more
Georgetown University20 enrolled3 locationsNCT05482516
Recruiting
Phase 3

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Metastatic Pancreatic Adenocarcinoma
Eleison Pharmaceuticals LLC.480 enrolled3 locationsNCT01954992
Recruiting
Phase 3

Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC

SurgeryPancreas CancerNeoadjuvant Chemotherapy+3 more
Sahlgrenska University Hospital432 enrolled1 locationNCT06714604
Recruiting
Phase 3

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

Pancreatic CancerPancreatic Ductal AdenocarcinomaResectable Pancreatic Adenocarcinoma
Erasmus Medical Center378 enrolled22 locationsNCT04927780
Recruiting
Phase 2Phase 3

Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP

Pancreatic Adenocarcinoma
Kochi University500 enrolled1 locationNCT05268692